Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice

BACKGROUND: Current clinical trials are using radiation therapy (RT) to enhance an antitumor response elicited by high-dose interleukin (IL)-2 therapy or immune checkpoint blockade (ICB). Bempegaldesleukin (BEMPEG) is an investigational CD122-preferential IL-2 pathway agonist with prolonged in vivo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Immunother Cancer
Hauptverfasser: Pieper, Alexander A, Rakhmilevich, Alexander L, Spiegelman, Daniel V, Patel, Ravi B, Birstler, Jen, Jin, Won Jong, Carlson, Peter M, Charych, Deborah H, Hank, Jacquelyn A, Erbe, Amy K, Overwijk, Willem W, Morris, Zachary S, Sondel, Paul M
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2021
Schlagworte:
Clinical/Translational Cancer Immunotherapy
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8237721/
https://ncbi.nlm.nih.gov/pubmed/34172518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002715
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge